Travere Therapeutics Inc (TVTX) is now in the Undervalued zone, suggesting that its current forward PS ratio of 5.90 is considered Undervalued compared with the five-year average of 40.12. The fair price of Travere Therapeutics Inc (TVTX) is between 53.10 to 68.93 according to relative valuation method. Compared to the current price of 29.53 USD , Travere Therapeutics Inc By Undervalued By 44.39%.

Relative Value

Fair Zone

53.10-68.93

Current Price：29.53

44.39%

Undervalued

P/E

EV/EBITDA

EV/EBIT

P/S

P/OCF

P/FCF

Trailing

Forward

Unlock 5-Year Valuation Change

Is Travere Therapeutics Inc (TVTX) at a historical peak or a rare bargain? Access the full 5-year trend to find out.

Unlock Now

Travere Therapeutics Inc (TVTX) has a current Price-to-Book (P/B) ratio of 48.06. Compared to its 3-year average P/B ratio of 16.62, the current P/B ratio is approximately 189.19% higher. Relative to its 5-year average P/B ratio of 13.42, the current P/B ratio is about 257.99% higher. Travere Therapeutics Inc (TVTX) has a Forward Free Cash Flow (FCF) yield of approximately -1.67%. Compared to its 3-year average FCF yield of -26.05%, the current FCF yield is approximately -93.60% lower. Relative to its 5-year average FCF yield of -17.15%, the current FCF yield is about -90.29% lower.

Competitors Valuation Multiple

AI Analysis

The average P/S ratio for TVTX competitors is 34.72, providing a benchmark for relative valuation. Travere Therapeutics Inc Corp (TVTX.O) exhibits a P/S ratio of 5.90, which is -82.99% above the industry average. Given its robust revenue growth of 73.41%, this premium appears sustainable.

P/E

P/S

EV/EBITDA

EV/EBIT

Earnings Growth

Market Cap

Performance Decomposition

AI Analysis

Market capitalization of TVTX increased by 0.00% over the past 1 year(s). The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00% to the performance.

Overall, the performance of TVTX in the past 1 year(s) is driven by Unknown.

People Also Watch

Frequently Asked Questions

Is TVTX currently overvalued or undervalued?

Travere Therapeutics Inc (TVTX) is now in the Undervalued zone, suggesting that its current forward PS ratio of 5.90 is considered Undervalued compared with the five-year average of 40.12. The fair price of Travere Therapeutics Inc (TVTX) is between 53.10 to 68.93 according to relative valuation method. Compared to the current price of 29.53 USD, Travere Therapeutics Inc is Undervalued By 44.39%.

What is Travere Therapeutics Inc (TVTX) fair value?

TVTX's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. The fair price of Travere Therapeutics Inc (TVTX) is between 53.10 to 68.93 according to relative valuation method.

How does TVTX's valuation metrics compare to the industry average?

The average P/S ratio for TVTX's competitors is 34.72, providing a benchmark for relative valuation. Travere Therapeutics Inc Corp (TVTX) exhibits a P/S ratio of 5.90, which is -82.99% above the industry average. Given its robust revenue growth of 73.41%, this premium appears sustainable.

What is the current P/B ratio for Travere Therapeutics Inc (TVTX) as of Mar 02 2026?

As of Mar 02 2026, Travere Therapeutics Inc (TVTX) has a P/B ratio of 48.06. This indicates that the market values TVTX at 48.06 times its book value.

What is the current FCF Yield for Travere Therapeutics Inc (TVTX) as of Mar 02 2026?

As of Mar 02 2026, Travere Therapeutics Inc (TVTX) has a FCF Yield of -1.67%. This means that for every dollar of Travere Therapeutics Inc's market capitalization, the company generates -1.67 cents in free cash flow.

What is the current Forward P/E ratio for Travere Therapeutics Inc (TVTX) as of Mar 02 2026?

As of Mar 02 2026, Travere Therapeutics Inc (TVTX) has a Forward P/E ratio of 39.39. This means the market is willing to pay $39.39 for every dollar of Travere Therapeutics Inc's expected earnings over the next 12 months.

What is the current Forward P/S ratio for Travere Therapeutics Inc (TVTX) as of Mar 02 2026?

As of Mar 02 2026, Travere Therapeutics Inc (TVTX) has a Forward P/S ratio of 5.90. This means the market is valuing TVTX at $5.90 for every dollar of expected revenue over the next 12 months.

TVTX Valuation